Stock SLNO SOLENO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Real-time Estimate Cboe BZX
Other stock markets
 12:18:04 2024-04-30 pm EDT 		5-day change 1st Jan Change
46.76 USD +2.71% Intraday chart for Soleno Therapeutics, Inc. +16.31% +15.99%
Apr. 29 Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment MT
Apr. 29 Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline DJ

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
AQ
Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment
MT
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline
DJ
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
AQ
Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
CI
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - April 19, 2024
AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Soleno Therapeutics Insider Sold Shares Worth $784,645, According to a Recent SEC Filing
MT
North American Morning Briefing : Investors -2-
DJ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
AQ
Soleno Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Soleno Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Soleno Therapeutics : March 2024 Corporate Presentation
PU
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
AQ
Piper Sandler Starts Soleno Therapeutics With Overweight Rating, $93 Price Target
MT
Soleno Therapeutics to Present at Upcoming February Investor Conferences
AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer
MT
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLNO Stock
  4. News Soleno Therapeutics, Inc.